Thales Laser on Mars 2020 Mission: Three Days to Touchdown
16.2.2021 01:40:00 EET | Business Wire | Press release
On 18 February, the Perseverance rover — a key component of the Mars 2020 mission — will touch down on the Red Planet after a long seven-month voyage. SuperCam, one of seven strategic onboard instruments, is a powerful combination of technologies designed to analyse, characterise and select Martian rock samples. SuperCam is the result of close collaboration between Los Alamos National Laboratory (LANL) in the United States and the astrophysics and planetology research institute in France (IRAP, CNRS / CNES / Université Toulouse III - Paul Sabatier), with contributions from the University of Hawaii and the University of Valladolid in Spain. The Mast Unit, the French part of SuperCam located at the top of the rover’s mast, was designed and built by a consortium of French laboratories1 from CNRS, universities and entities under the scientific lead of the IRAP team and under the responsibility of CNES, the French space agency. The laser supplied by Thales is a key part of the Mast Unit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210215005423/en/
Credits: NASA
In 2012, Curiosity landed on Mars equipped with the first high-power laser to operate on the surface of another planet, a laser designed and developed by Thales for the ChemCam instrument. The ChemCam laser has been operating faultlessly for over eight years and has fired close to 855,000 shots to date as Curiosity has made its 24-kilometre trek across the surface of the Red Planet. Data from ChemCam has already helped to prove that conditions on Mars were once suitable for microbial life.
The SuperCam instrument, a new and more powerful version of ChemCam, is designed to take Mars exploration to a new level. Like ChemCam, the SuperCam laser will use an infrared beam to heat material to a temperature of around 10,000°C and vaporise it — a method called laser induced breakdown spectroscopy. Coupled with a special camera, this makes it possible to determine the chemical composition of Martian rock samples by measuring the colours of light in the plasma created.
Unlike ChemCam, however, the SuperCam laser can also emit a green laser beam, which will help determine the molecular composition of surface materials. This green beam excites the chemical bonds in samples and produces a different signal according to their various linked components. This analysis technique, known as Raman spectroscopy, will be tested for the first time on Mars and will enable scientists to detect any markers of life. The green laser will also be used to induce fluorescence in mineral and organic compounds, allowing scientists to determine their constituent components with greater accuracy.
“We’re proud to have provided NASA with the first two lasers to operate on Mars. The Mars 2020 mission is a decisive step forward in the study of the Red Planet and preparations for future expeditions. SuperCam, the ‘eyes’ of Perseverance, is the result of close collaboration between partners across the international scientific community. Thales's SuperCam laser delivers unrivalled performance and will enable Perseverance to perform its exploration mission throughout its time on the surface of Mars.” Christophe Salomon, Executive Vice President, Land and Air Systems
About Mars 2020
The goal of the Mars 2020 mission is to study the Red Planet’s surface, search for signs of past life, take rock and dust samples at selected sites and store them for retrieval by the future Mars Sample Return (MSR) mission, which will be conducted jointly with the European Space Agency. Thales Alenia Space is closely involved in the MSR mission.
The Mars 2020 mission is designed to gather the necessary knowledge and test the technologies that will be vital for future human expeditions to the Red Planet.
How to produce oxygen from the Martian atmosphere? What resources are available? Is there water beneath the surface, for example? How to improve landing techniques and characterise weather conditions, dust levels and other environmental conditions that could affect the life and work of future astronauts on Mars? These are just some of the questions the Perseverance mission will seek to answer.
About Thales lasers
For more than 35 years, Thales has been a world leader in design, development and manufacturing of high energy nanosecond lasers for industrial applications and the most powerful ultra-short Ti:Sa femtosecond laser systems for leading scientific applications with peak power up to 10 petawatts.
Thales provides the most reliable and easy-to-use products, a unique combination of technological expertise and robustness for implementation into industrial applications that require highest availability such as laser annealing, laser lift-off, laser shock peening and cutting of composites for various industries such as aerospace, microelectronics, flat panel displays and many others. Thales provides also a full range of services, which are optimized to support each customer.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
[1] The Irap ; the Laboratoire d’études spatiales et d’instrumentation en astrophysique (LESIA, Observatoire de Paris-PSL/CNRS/SU/Université de Paris) ; the Laboratoire d’astrophysique de Bordeaux (LAB, CNRS/Université de Bordeaux) ; the Laboratoire « atmosphères et observations spatiales » (LATMOS, CNRS/SU/UVSQ) ; l’Observatoire Midi-Pyrénées (OMP, CNRS/IRD/Météo-France/Université de Toulouse III – Paul Sabatier) ; the Institut d’astrophysique spatiale (IAS, CNRS/Université Paris-Saclay).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005423/en/
Contact information
PRESS
Thales, Media Relations
Group and Innovation
Alice Pruvot
+33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
Thales Alenia Space, Media Relations
Sandrine Bielecki
+33 (0)4 92 92 70 94
sandrine.bielecki@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release
Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito
National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom